

# Kochupurackal P Mohanakumar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4782164/publications.pdf>

Version: 2024-02-01

110  
papers

4,178  
citations

101543

36  
h-index

128289

60  
g-index

110  
all docs

110  
docs citations

110  
times ranked

4395  
citing authors

#	ARTICLE	IF	CITATIONS
1	Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. FASEB Journal, 1998, 12, 905-912.	0.5	219
2	Quercetin up-regulates mitochondrial complex-I activity to protect against programmed cell death in rotenone model of Parkinson's disease in rats. Neuroscience, 2013, 236, 136-148.	2.3	179
3	Association of L-DOPA with recovery following Ayurveda medication in Parkinson's disease. Journal of the Neurological Sciences, 2000, 176, 124-127.	0.6	122
4	Melatonin protects against rotenone-induced oxidative stress in a hemiparkinsonian rat model. Journal of Pineal Research, 2007, 42, 247-253.	7.4	114
5	Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. Brain Research, 2000, 864, 281-290.	2.2	113
6	Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease. Brain Research, 2005, 1049, 147-155.	2.2	111
7	Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Brain Research, 2003, 966, 245-252.	2.2	107
8	Melatonin protects against oxidative stress caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the mouse nigrostriatum. Journal of Pineal Research, 2004, 36, 25-32.	7.4	106
9	<i>In Vivo</i> Generation of Hydroxyl Radicals and MPTP-Induced Dopaminergic Toxicity in the Basal Ganglia. Annals of the New York Academy of Sciences, 1994, 738, 25-36.	3.8	104
10	Ferrous Citrate Complex and Nigral Degeneration: Evidence for Free Radical Formation and Lipid Peroxidation. Annals of the New York Academy of Sciences, 1994, 738, 392-399.	3.8	104
11	Manganese: A transition metal protects nigrostriatal neurons from oxidative stress in the iron-induced animal model of Parkinsonism. Neuroscience, 1998, 85, 1101-1111.	2.3	103
12	Quercetin Improves Behavioral Deficiencies, Restores Astrocytes and Microglia, and Reduces Serotonin Metabolism in 3-Nitropropionic Acid-Induced Rat Model of Huntington's Disease. CNS Neuroscience and Therapeutics, 2014, 20, 10-19.	3.9	101
13	Apparent Role of Hydroxyl Radicals in Oxidative Brain Injury Induced by Sodium Nitroprusside. Free Radical Biology and Medicine, 1998, 24, 1065-1073.	2.9	95
14	Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: A comparative study in two mouse strains. Behavioural Brain Research, 2005, 163, 159-167.	2.2	88
15	S-nitrosothiols and nitric oxide, but not sodium nitroprusside, protect nigrostriatal dopamine neurons against iron-induced oxidative stress in vivo. , 1996, 23, 58-60.		85
16	Nitric Oxide. Annals of the New York Academy of Sciences, 2002, 962, 389-401.	3.8	83
17	Neuroprotective Potential of Silymarin against CNS Disorders: Insight into the Pathways and Molecular Mechanisms of Action. CNS Neuroscience and Therapeutics, 2013, 19, 847-853.	3.9	79
18	l-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats. Neurochemistry International, 2006, 49, 28-40.	3.8	78

#	ARTICLE	IF	CITATIONS
19	Acetaminophen and aspirin inhibit superoxide anion generation and lipid peroxidation, and protect against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. <i>Neurochemistry International</i> , 2004, 44, 355-360.	3.8	76
20	Mitochondrial NAD <sup>+</sup> -linked State 3 respiration and complex I activity are compromised in the cerebral cortex of 3-nitropropionic acid-induced rat model of Huntington's disease. <i>Journal of Neurochemistry</i> , 2008, 104, 420-434.	3.9	73
21	Behavioral differences in a rotenone-induced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion. <i>Brain Research</i> , 2005, 1051, 25-34.	2.2	71
22	Neuroprotection by nitric oxide against hydroxyl radical-induced nigral neurotoxicity. <i>Journal of Chemical Neuroanatomy</i> , 1998, 14, 195-205.	2.1	63
23	Melatonin inhibits 6-hydroxydopamine production in the brain to protect against experimental parkinsonism in rodents. <i>Journal of Pineal Research</i> , 2009, 47, 293-300.	7.4	62
24	Long-Term L-DOPA Treatment Causes Indiscriminate Increase in Dopamine Levels at the Cost of Serotonin Synthesis in Discrete Brain Regions of Rats. <i>Cellular and Molecular Neurobiology</i> , 2007, 27, 985-996.	3.3	60
25	Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice. <i>Journal of Pineal Research</i> , 2015, 58, 262-274.	7.4	60
26	Hypothyroidism in the developing rat brain is associated with marked oxidative stress and aberrant intraneuronal accumulation of neurofilaments. <i>Neuroscience Research</i> , 2001, 40, 273-279.	1.9	58
27	Antioxidant Mechanism and Protection of Nigral Neurons Against MPP <sup>+</sup> Toxicity by Deprenyl (Selegiline). <i>Annals of the New York Academy of Sciences</i> , 1994, 738, 214-221.	3.8	55
28	In vivo hydroxyl radical generation in the striatum following systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. <i>Brain Research</i> , 2000, 852, 221-224.	2.2	52
29	Rats with unilateral median forebrain bundle, but not striatal or nigral, lesions by the neurotoxins MPP <sup>+</sup> or rotenone display differential sensitivity to amphetamine and apomorphine. <i>Pharmacology Biochemistry and Behavior</i> , 2006, 84, 321-329.	2.9	49
30	Low Levels of Prohibitin in Substantia Nigra Makes Dopaminergic Neurons Vulnerable in Parkinson's Disease. <i>Molecular Neurobiology</i> , 2018, 55, 804-821.	4.0	47
31	D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity. <i>Synapse</i> , 2003, 50, 7-13.	1.2	44
32	Aging and Neurodegeneration: A Tangle of Models and Mechanisms. , 2016, 7, 111.		44
33	Nimodipine, an L-type calcium channel blocker attenuates mitochondrial dysfunctions to protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice. <i>Neurochemistry International</i> , 2016, 99, 221-232.	3.8	44
34	In vitro and in vivo evidences that antioxidant action contributes to the neuroprotective effects of the neuronal nitric oxide synthase and monoamine oxidase-B inhibitor, 7-nitroindazole. <i>Neurochemistry International</i> , 2008, 52, 990-1001.	3.8	43
35	Melatonin synergizes with low doses of L-DOPA to improve dendritic spine density in the mouse striatum in experimental Parkinsonism. <i>Journal of Pineal Research</i> , 2013, 55, 304-312.	7.4	42
36	Dissociation of serotonergic and dopaminergic components in acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. <i>Brain Research Bulletin</i> , 1992, 28, 355-364.	3.0	41

#	ARTICLE	IF	CITATIONS
37	Resistance of Golden Hamster to 1-Methyl-2,3,6-Tetrahydropyridine: Relationship with Low Levels of Regional Monoamine Oxidase B. <i>Journal of Neurochemistry</i> , 1994, 62, 1906-1912.	3.9	40
38	Sexual dimorphic effect in the genetic association of monoamine oxidase A (MAOA) markers with autism spectrum disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014, 50, 11-20.	4.8	39
39	Melatonin protects against behavioural dysfunctions and dendritic spine damage in 3-nitropropionic acid-induced rat model of Huntington's disease. <i>Behavioural Brain Research</i> , 2014, 264, 91-104.	2.2	38
40	Neuro-nutraceuticals: The path to brain health via nourishment is not so distant. <i>Neurochemistry International</i> , 2015, 89, 1-6.	3.8	38
41	Attention deficit-hyperactivity disorder suffers from mitochondrial dysfunction. <i>BBA Clinical</i> , 2016, 6, 153-158.	4.1	38
42	Unilateral implantation of dopamine-loaded biodegradable hydrogel in the striatum attenuates motor abnormalities in the 6-hydroxydopamine model of hemi-parkinsonism. <i>Behavioural Brain Research</i> , 2007, 184, 11-18.	2.2	37
43	Antiparkinsonian Effects of Aqueous Methanolic Extract of <i>Hyoscyamus niger</i> Seeds Result From its Monoamine Oxidase Inhibitory and Hydroxyl Radical Scavenging Potency. <i>Neurochemical Research</i> , 2011, 36, 177-186.	3.3	37
44	Serotonin synthesis inhibition in olivo-cerebellar system attenuates harmaline-induced tremor in Swiss albino mice. <i>Behavioural Brain Research</i> , 2003, 145, 31-36.	2.2	33
45	Tea and Parkinson's disease: Constituents of tea synergize with antiparkinsonian drugs to provide better therapeutic benefits. <i>Neurochemistry International</i> , 2015, 89, 181-190.	3.8	32
46	L-DOPA induced-endogenous 6-hydroxydopamine is the cause of aggravated dopaminergic neurodegeneration in Parkinson's disease patients. <i>Medical Hypotheses</i> , 2012, 79, 271-273.	1.5	31
47	Mitochondrial Deficits Accompany Cognitive Decline Following Single Bilateral Intracerebroventricular Streptozotocin. <i>Current Alzheimer Research</i> , 2015, 12, 785-795.	1.4	31
48	SLC6A4 markers modulate platelet 5-HT level and specific behaviors of autism: A study from an Indian population. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2015, 56, 196-206.	4.8	30
49	Mitochondrial functional alterations in relation to pathophysiology of Huntington's disease. <i>Journal of Bioenergetics and Biomembranes</i> , 2010, 42, 217-226.	2.3	29
50	2-Phenylethylamine, a constituent of chocolate and wine, causes mitochondrial complex-I inhibition, generation of hydroxyl radicals and depletion of striatal biogenic amines leading to psycho-motor dysfunctions in Balb/c mice. <i>Neurochemistry International</i> , 2010, 57, 637-646.	3.8	28
51	Nitric oxide synthase inhibitors protect against rotenone-induced, oxidative stress mediated parkinsonism in rats. <i>Neurochemistry International</i> , 2013, 62, 674-683.	3.8	28
52	Can Cyclic Nucleotide Phosphodiesterase Inhibitors Be Drugs for Parkinson's Disease?. <i>Molecular Neurobiology</i> , 2018, 55, 822-834.	4.0	28
53	Aspirin Curtails the Acetaminophen-Induced Rise in Brain Norepinephrine Levels. <i>Metabolic Brain Disease</i> , 2004, 19, 71-77.	2.9	27
54	Reduced NADH coenzyme Q dehydrogenase activity in platelets of Parkinson's disease, but not Parkinson plus patients, from an Indian population. <i>Journal of the Neurological Sciences</i> , 2009, 279, 39-42.	0.6	26

#	ARTICLE	IF	CITATIONS
55	L-DOPA-induced 6-hydroxydopamine production in the striata of rodents is sensitive to the degree of denervation. <i>Neurochemistry International</i> , 2010, 56, 357-362.	3.8	26
56	Sodium salicylate protects against rotenone-induced Parkinsonism in rats. <i>Synapse</i> , 2013, 67, 502-514.	1.2	26
57	Reinforcing mitochondrial functions in aging brain: An insight into Parkinson's disease therapeutics. <i>Journal of Chemical Neuroanatomy</i> , 2019, 95, 29-42.	2.1	25
58	Striatal dopamine level contributes to hydroxyl radical generation and subsequent neurodegeneration in the striatum in 3-nitropropionic acid-induced Huntington's disease in rats. <i>Neurochemistry International</i> , 2009, 55, 431-437.	3.8	24
59	Serotonin mediated immunoregulation and neural functions: Complicity in the aetiology of autism spectrum disorders. <i>Neuroscience and Biobehavioral Reviews</i> , 2015, 55, 413-431.	6.1	23
60	Acute intranigral homocysteine administration produces stereotypic behavioral changes and striatal dopamine depletion in Spragueâ€Dawley rats. <i>Brain Research</i> , 2006, 1075, 81-92.	2.2	22
61	Neuro-nutraceuticals: Further insights into their promise for brain health. <i>Neurochemistry International</i> , 2016, 95, 1-3.	3.8	21
62	Salicylic acid protects against chronic L-DOPA-induced 6-OHDA generation in experimental model of parkinsonism. <i>Brain Research</i> , 2010, 1344, 192-199.	2.2	20
63	Genetic variants of MAOB affect serotonin level and specific behavioral attributes to increase autism spectrum disorder (ASD) susceptibility in males. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 71, 123-136.	4.8	20
64	Effects of serotonergic drugs on tremor induced by physostigmine in rats. <i>Behavioural Brain Research</i> , 2000, 109, 187-193.	2.2	19
65	Quercetin improves the activity of the ubiquitinâ€proteasomal system in 150Q mutated huntingtinâ€expressing cells but exerts detrimental effects on neuronal survivability. <i>Journal of Neuroscience Research</i> , 2015, 93, 1581-1591.	2.9	18
66	Nimodipine attenuates the parkinsonian neurotoxin, MPTP-induced changes in the calcium binding proteins, calpain and calbindin. <i>Journal of Chemical Neuroanatomy</i> , 2019, 95, 89-94.	2.1	18
67	Antagonistic pleiotropic effects of nitric oxide in the pathophysiology of Parkinson's disease. <i>Free Radical Research</i> , 2015, 49, 1129-1139.	3.3	17
68	Tremorogenesis by physostigmine is unrelated to acetylcholinesterase inhibition: Evidence for serotonergic involvement. <i>Neuroscience Letters</i> , 1990, 120, 91-93.	2.1	15
69	A mitochondrial basis for Huntingtonâ€™s disease: therapeutic prospects. <i>Molecular and Cellular Biochemistry</i> , 2014, 389, 277-291.	3.1	14
70	Effects of p-chlorophenylalanine on striatal acetylcholinesterase activity and on biogenic amine levels in nuclei raphe and caudate-putamen during physostigmine-induced tremor in rats. <i>Neuroscience Letters</i> , 2001, 299, 105-108.	2.1	13
71	Calcium channel agonist, (Â±)-Bay K8644, causes a transient increase in striatal monoamine oxidase activity in Balb/c mice. <i>Neuroscience Letters</i> , 2003, 342, 73-76.	2.1	13
72	Apoptotic Mode of Cell Death in Substantia Nigra Following Intranigral Infusion of the Parkinsonian Neurotoxin, MPP+ in Sprague-Dawley Rats: Cellular, Molecular and Ultrastructural Evidences. <i>Neurochemical Research</i> , 2007, 32, 1238-1247.	3.3	13

#	ARTICLE	IF	CITATIONS
73	Parkinson's disease cybrids, differentiated or undifferentiated, maintain morphological and biochemical phenotypes different from those of control cybrids. <i>Journal of Neuroscience Research</i> , 2013, 91, 963-970.	2.9	13
74	Gender-Specific Effect of 5-HT and 5-HIAA on Threshold Level of Behavioral Symptoms and Sex-Bias in Prevalence of Autism Spectrum Disorder. <i>Frontiers in Neuroscience</i> , 2019, 13, 1375.	2.8	13
75	Acetylcholinesterase changes in the central nervous system of mice during the development of morphine tolerance addiction and withdrawal. <i>Brain Research Bulletin</i> , 1983, 10, 589-596.	3.0	12
76	Potential Contribution of Monoamine Oxidase A Gene Variants in ADHD and Behavioral Co-Morbidities: Scenario in Eastern Indian Probands. <i>Neurochemical Research</i> , 2014, 39, 843-852.	3.3	12
77	Engraftment of Mouse Embryonic Stem Cells Differentiated by Default Leads to Neuroprotection, Behaviour Revival and Astrogliosis in Parkinsonian Rats. <i>PLoS ONE</i> , 2013, 8, e72501.	2.5	12
78	Evidence for the involvement of central serotonergic mechanisms in cholinergic tremor induced by tacrine in Balb/c mice. <i>Behavioural Brain Research</i> , 2005, 163, 227-236.	2.2	11
79	Intrastriatal infusion of the Parkinsonian neurotoxin, MPP+, induces damage of striatal cell nuclei in Spragueâ€Dawley rats. <i>Journal of Chemical Neuroanatomy</i> , 2006, 32, 90-100.	2.1	11
80	Profilin-2 increased expression and its altered interaction with $\beta$ -actin in the striatum of 3-nitropropionic acid-induced Huntingtonâ€™s disease in rats. <i>Neuroscience</i> , 2014, 281, 216-228.	2.3	11
81	Pilot study indicate role of preferentially transmitted monoamine oxidase gene variants in behavioral problems of male ADHD probands. <i>BMC Medical Genetics</i> , 2017, 18, 109.	2.1	11
82	Long term L-DOPA treatment causes production of 6-OHDA in the mouse striatum: Involvement of hydroxyl radical. <i>Annals of Neurosciences</i> , 2009, 16, 160-165.	1.7	11
83	Evidence for Hydroxyl Radical Scavenging Action of Nitric Oxide Donors in the Protection Against 1-Methyl-4-phenylpyridinium-induced Neurotoxicity in Rats. <i>Neurochemical Research</i> , 2008, 33, 985-995.	3.3	10
84	Earlyâ€Life treatment of antiserotonin antibodies alters sensitivity to serotonin receptors, nociceptive stimulus and serotonin metabolism in adult rats. <i>International Journal of Developmental Neuroscience</i> , 2010, 28, 317-324.	1.6	10
85	Region-specific attenuation of a trypsin-like protease in substantia nigra following dopaminergic neurotoxicity by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. <i>Brain Research</i> , 2000, 882, 191-195.	2.2	9
86	Atropine, a muscarinic cholinergic receptor antagonist increases serotonin, but not dopamine levels in discrete brain regions of mice. <i>Neuroscience Letters</i> , 2007, 423, 100-103.	2.1	9
87	Taurine fails to protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced striatal dopamine depletion in mice. <i>Amino Acids</i> , 2008, 35, 457-461.	2.7	9
88	Neonatal treatment with 5-HT antiserum alters 5-HT metabolism and function in adult rats. <i>NeuroReport</i> , 1995, 7, 238-240.	1.2	9
89	Tremorogenesis by LON-954 [N-carbamoyl-2-(2,6-dichlorophenyl) acetamidine hydrochloride]: Evidence for the involvement of 5-hydroxytryptamine. <i>Brain Research Bulletin</i> , 1989, 22, 191-195.	3.0	8
90	Calcium channel agonist, ( $\hat{A}$ )-Bay K8644, causes an immediate increase in the striatal 1-methyl-4-phenylpyridinium level following systemic administration of the dopaminergic neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, in Balb/c mice. <i>Neuroscience Letters</i> , 2003, 346, 69-72.	2.1	8

#	ARTICLE	IF	CITATIONS
91	A synthetic human proline-rich-polypeptide enhances hydroxyl radical generation and fails to protect dopaminergic neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced toxicity in mice. <i>Neuroscience Letters</i> , 2005, 375, 187-191.	2.1	8
92	Neurochemical Mechanisms Underlying Neuroprotective Actions of Bromocriptine, Salicylate, d- and L-Deprenyl in Neurodegeneration caused by MPTP. , 2000, , 289-293.		8
93	Monoamine oxidase B gene variants associated with attention deficit hyperactivity disorder in the Indo-Caucasoid population from West Bengal. <i>BMC Genetics</i> , 2016, 17, 92.	2.7	7
94	The Parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on membrane currents and intrasynaptosomal calcium. <i>Neuroscience Research Communications</i> , 2002, 30, 35-42.	0.2	6
95	Synthetic bovine proline-rich-polypeptides generate hydroxyl radicals and fail to protect dopaminergic neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity in mice. <i>Neuropeptides</i> , 2006, 40, 291-298.	2.2	6
96	Regenerative Therapy in Experimental Parkinsonism: Mixed Population of Differentiated Mouse Embryonic Stem Cells, Rather Than Magnetically Sorted and Enriched Dopaminergic Cells Provide Neuroprotection. <i>CNS Neuroscience and Therapeutics</i> , 2014, 20, 717-727.	3.9	6
97	5-Hydroxytryptamine in the phrenic nerve diaphragm: Evidence for its existence and release. <i>Neuroscience Letters</i> , 1989, 97, 345-349.	2.1	5
98	Supersensitivity of spinal dopaminergic receptors in rat after chronic haloperidol. <i>Brain Research Bulletin</i> , 1992, 28, 133-135.	3.0	5
99	Neuro-nutraceuticals: Natural products nourish the brain but be aware of contrary effects. <i>Neurochemistry International</i> , 2021, 150, 105159.	3.8	5
100	Behavioral and neurochemical alterations following intracerebroventricular administration of anti-serotonin antibodies in adult Balb/c mice. <i>Journal of Chemical Neuroanatomy</i> , 1998, 14, 141-149.	2.1	4
101	Embryonic Stem Cells Derived Neuron Transplantation Recovery in Models of Parkinsonism in Relation to Severity of the Disorder in Rats. <i>Rejuvenation Research</i> , 2015, 18, 173-184.	1.8	4
102	Fluctuations of acetylcholinesterase in the mouse spinal cord and in vivo sodium effect during the development of morphine tolerance, dependence, and withdrawal. <i>Neurochemical Research</i> , 1986, 11, 505-520.	3.3	3
103	The Legacy of Nitric Oxide: Impact on Disease Biology. <i>Nitric Oxide - Biology and Chemistry</i> , 2014, 43, 1-2.	2.7	3
104	The light at the end of the tunnel gets vivid for spinal muscular atrophy. <i>Journal of Neurochemistry</i> , 2020, 153, 545-548.	3.9	2
105	Glycosidases and Lipid Metabolism in the Central Nervous System of the Hedgehog (&lt;i>&lt;i>Paraechinus micropus&lt;/i&lt;/i>). <i>Cells Tissues Organs</i> , 1982, 114, 339-346.	2.3	1
106	Ayurveda in Parkinson&#x2013;s disease. <i>Journal of the Neurological Sciences</i> , 2001, 184, 91-92.	0.6	1
107	Synthesis of Fluorinated 2,3-Disubstituted Benzofurans Potential $\beta$ -Amyloid Aggregation Inhibitors. <i>Heterocycles</i> , 2010, 80, 663.	0.7	1
108	Neural functions of the aging brain: Daily living, developmental and geriatric disabilities. <i>Journal of Chemical Neuroanatomy</i> , 2019, 95, 1-5.	2.1	1

#	ARTICLE	IF	CITATIONS
109	Neonatal treatment with 5-HT antiserum alters 5-HT metabolism and function in adult rats. NeuroReport, 1995, 7, 238-240.	1.2	1
110	Distribution of Carboxylic Esterases in the Telencephalon and Diencephalon of a Microchiropteran Bat (<i>Taphozous melanopogo</i>; Temminck). Cells Tissues Organs, 1983, 116, 312-321.	2.3	0